Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | PDE6D | O43924 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242353 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL20242692 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL22828152 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL20242719 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL23702524 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL23702538 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL21271726 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL22828168 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL21271665 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL30189622 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | claimed |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3947368-B1 | BIFUNCTIONAL COMPOUNDS COMPRISING A CDK2/5 LIGAND, A LINKER AND A E3 UBIQUITIN LIGASE BINDING DEGRON FOR THE TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| US-12186401-B2 | Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses | Ontario Institute for Cancer Research (OICR) and Sinai Health System (CA) | 2025-01-07 | — | — | US | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3947368-A1 | CDK2/5 DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-08-22 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | STAT3 1923/4885CRBN 120/4885DDB1 350/4885 |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | STAT3 719/4885CRBN 151/4885DDB1 313/4885 |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | STAT3 1923/4885CRBN 120/4885DDB1 350/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | STAT3 146/4885CRBN 929/4885DDB1 2514/4885 |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | CDK2, CDK5, CDK5R1 | STAT3 1656/4885CRBN 277/4885DDB1 263/4885 |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | MDM2, CD74, TNFSF10 | STAT3 719/4885CRBN 151/4885DDB1 313/4885 |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | STAT3 998/4885CRBN 527/4885DDB1 1141/4885 |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | STAT3 998/4885CRBN 527/4885DDB1 1141/4885 |
| US-12186401-B2 | Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses | BRAF, RAF1, BAP1 | STAT3 2877/4885CRBN 265/4885DDB1 216/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | STAT3 1923/4885CRBN 120/4885DDB1 350/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | STAT3 719/4885CRBN 151/4885DDB1 313/4885 |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | STAT3 1923/4885CRBN 120/4885DDB1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.